English
简体中文
Total: £ 56.28
Published Date: 2026-01-08 | Pages: 108 | Tables: 113 | Pharma & Healthcare
The global Hepatitis B Vaccines market was valued at US$ 1456 million in 2025 and is anticipated to reach US$ 2287 million by 2032, at a CAGR of 6.5% from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Hepatitis B Vaccines competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Hepatitis B vaccine is a vaccine that prevents hepatitis B. The first dose is recommended within 24 hours of birth with either two or three more doses given after that. This includes those with poor immune function such as from HIV/AIDS and those born premature. It is also recommended that health-care workers be vaccinated. In healthy people routine immunization results in more than 95% of people being protected.In 2025, global Hepatitis B vaccine production reached approximately 391 million doses and price si about 3.72 USD/dose.The average gross profit margin of this product is 70%.
The fundamental drivers of the HepB vaccine market are the certainty of national immunization programs and long-term public-health goals tied to reducing HBV-related burden. Routine infant and pediatric vaccination provides a stable demand base in many regions, while increasingly risk-stratified adult prevention makes demand more visible across occupational exposure groups, people with chronic conditions or immunocompromise, and settings shaped by mobility and cross-border travel. In parallel, the market is evolving from single-product supply toward combination and service-enabled ecosystems, where supply stability, release capacity, cold-chain reach, and channel depth become durable competitive advantages.
As a highly regulated biologic, HepB vaccines face challenges centered on quality consistency and supply reliability. From antigen expression and purification to adjuvant compatibility and fill-finish, small process variations can escalate into batch-release and reputational risks. Public trust is also critical: safety communication, pharmacovigilance, and adverse-event management must be systematic and credible. Structurally, mature program markets may intensify price- and tender-driven commoditization, while adult and international markets depend on indication strategy, vaccination adherence, and affordability to convert potential demand into realized uptake.
Downstream demand is shifting from “coverage-driven” to “population precision and life-course management.” Pediatric pathways increasingly integrate with perinatal and maternal–child health workflows, while adult pathways emphasize high-risk identification, occupational-health linkage, and standardized post-exposure prevention routines. Another notable trend is the structural impact of combination vaccines and convenience: simpler schedules and more digital follow-up can materially improve catch-up and adult access. At the same time, mobility and global health collaboration raise expectations for stable supply, traceability systems, and multi-jurisdiction compliance readiness.
Upstream value concentrates on the biomanufacturing inputs required for recombinant antigen production and sterile drug-product processing: cell banks/strains and media systems, fermentation or cell-culture consumables, purification materials such as chromatography resins and ultrafiltration membranes, and formulation components including adjuvants, buffers, and stabilizers. In fill-finish and packaging, consistency requirements extend to vials or prefilled syringes, stoppers and seals, labeling and serialization/traceability, and cold-chain packaging materials. Overall, the grade, continuity, and change-control discipline of upstream supplies directly shape batch-to-batch consistency, release efficiency, and predictable scale delivery.
This report delivers a comprehensive overview of the global Hepatitis B Vaccines market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Hepatitis B Vaccines. The Hepatitis B Vaccines market size, estimates, and forecasts are provided in terms of sales volume (M Doses) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Hepatitis B Vaccines market comprehensively. Regional market sizes by Type, by Application, by Form Factor & Presentation, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Hepatitis B Vaccines manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
GSK
NCPC
Merck
Bio Kangtai
Dynavax
AIM Vaccine
KM Biologics
LG Life Sciences
Serum Institute
Segment by Type
Yeast Derived
CHO Derived
Segment by Form Factor & Presentation
Vial Presentation
Prefilled Syringe
Segment by Adjuvant System
Aluminum Salt Adjuvant
No Adjuvant
Other
by Application
Children
Adult
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Form Factor & Presentation, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Hepatitis B Vaccines manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Hepatitis B Vaccines sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Hepatitis B Vaccines Market Overview
1.1 Product Definition
1.2 Hepatitis B Vaccines by Type
1.2.1 Global Hepatitis B Vaccines Market Value by Type: 2025 vs 2032
1.2.2 Yeast Derived
1.2.3 CHO Derived
1.3 Hepatitis B Vaccines by Form Factor & Presentation
1.3.1 Global Hepatitis B Vaccines Market Value by Form Factor & Presentation: 2025 vs 2032
1.3.2 Vial Presentation
1.3.3 Prefilled Syringe
1.4 Hepatitis B Vaccines by Adjuvant System
1.4.1 Global Hepatitis B Vaccines Market Value by Adjuvant System: 2025 vs 2032
1.4.2 Aluminum Salt Adjuvant
1.4.3 No Adjuvant
1.4.4 Other
1.5 Hepatitis B Vaccines by Application
1.5.1 Global Hepatitis B Vaccines Market Value by Application: 2025 vs 2032
1.5.2 Children
1.5.3 Adult
1.6 Global Hepatitis B Vaccines Market Size Estimates and Forecasts
1.6.1 Global Hepatitis B Vaccines Revenue 2021–2032
1.6.2 Global Hepatitis B Vaccines Sales 2021–2032
1.6.3 Global Hepatitis B Vaccines Market Average Price (2021–2032)
1.7 Assumptions and Limitations
2 Hepatitis B Vaccines Market Competition by Manufacturers
2.1 Global Hepatitis B Vaccines Sales Market Share by Manufacturers (2021–2026)
2.2 Global Hepatitis B Vaccines Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Hepatitis B Vaccines Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Hepatitis B Vaccines, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Hepatitis B Vaccines, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Hepatitis B Vaccines, Product Types and Applications
2.7 Global Key Manufacturers of Hepatitis B Vaccines, Date of Entry into the Industry
2.8 Global Hepatitis B Vaccines Market Competitive Situation and Trends
2.8.1 Global Hepatitis B Vaccines Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Hepatitis B Vaccines Players Market Share by Revenue
2.8.3 Global Hepatitis B Vaccines Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Hepatitis B Vaccines Market Scenario by Region
3.1 Global Hepatitis B Vaccines Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Hepatitis B Vaccines Sales by Region: 2021–2032
3.2.1 Global Hepatitis B Vaccines Sales by Region: 2021–2026
3.2.2 Global Hepatitis B Vaccines Sales by Region: 2027–2032
3.3 Global Hepatitis B Vaccines Revenue by Region: 2021–2032
3.3.1 Global Hepatitis B Vaccines Revenue by Region: 2021–2026
3.3.2 Global Hepatitis B Vaccines Revenue by Region: 2027–2032
3.4 North America Hepatitis B Vaccines Market Facts & Figures by Country
3.4.1 North America Hepatitis B Vaccines Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Hepatitis B Vaccines Sales by Country (2021–2032)
3.4.3 North America Hepatitis B Vaccines Revenue by Country (2021–2032)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Hepatitis B Vaccines Market Facts & Figures by Country
3.5.1 Europe Hepatitis B Vaccines Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Hepatitis B Vaccines Sales by Country (2021–2032)
3.5.3 Europe Hepatitis B Vaccines Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Hepatitis B Vaccines Market Facts & Figures by Region
3.6.1 Asia Pacific Hepatitis B Vaccines Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Hepatitis B Vaccines Sales by Region (2021–2032)
3.6.3 Asia Pacific Hepatitis B Vaccines Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Hepatitis B Vaccines Market Facts & Figures by Country
3.7.1 Latin America Hepatitis B Vaccines Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Hepatitis B Vaccines Sales by Country (2021–2032)
3.7.3 Latin America Hepatitis B Vaccines Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Hepatitis B Vaccines Market Facts & Figures by Country
3.8.1 Middle East and Africa Hepatitis B Vaccines Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Hepatitis B Vaccines Sales by Country (2021–2032)
3.8.3 Middle East and Africa Hepatitis B Vaccines Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Hepatitis B Vaccines Sales by Type (2021–2032)
4.1.1 Global Hepatitis B Vaccines Sales by Type (2021–2026)
4.1.2 Global Hepatitis B Vaccines Sales by Type (2027–2032)
4.1.3 Global Hepatitis B Vaccines Sales Market Share by Type (2021–2032)
4.2 Global Hepatitis B Vaccines Revenue by Type (2021–2032)
4.2.1 Global Hepatitis B Vaccines Revenue by Type (2021–2026)
4.2.2 Global Hepatitis B Vaccines Revenue by Type (2027–2032)
4.2.3 Global Hepatitis B Vaccines Revenue Market Share by Type (2021–2032)
4.3 Global Hepatitis B Vaccines Price by Type (2021–2032)
5 Segment by Application
5.1 Global Hepatitis B Vaccines Sales by Application (2021–2032)
5.1.1 Global Hepatitis B Vaccines Sales by Application (2021–2026)
5.1.2 Global Hepatitis B Vaccines Sales by Application (2027–2032)
5.1.3 Global Hepatitis B Vaccines Sales Market Share by Application (2021–2032)
5.2 Global Hepatitis B Vaccines Revenue by Application (2021–2032)
5.2.1 Global Hepatitis B Vaccines Revenue by Application (2021–2026)
5.2.2 Global Hepatitis B Vaccines Revenue by Application (2027–2032)
5.2.3 Global Hepatitis B Vaccines Revenue Market Share by Application (2021–2032)
5.3 Global Hepatitis B Vaccines Price by Application (2021–2032)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Company Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK Hepatitis B Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 GSK Hepatitis B Vaccines Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 NCPC
6.2.1 NCPC Company Information
6.2.2 NCPC Description and Business Overview
6.2.3 NCPC Hepatitis B Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 NCPC Hepatitis B Vaccines Product Portfolio
6.2.5 NCPC Recent Developments/Updates
6.3 Merck
6.3.1 Merck Company Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Hepatitis B Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Merck Hepatitis B Vaccines Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 Bio Kangtai
6.4.1 Bio Kangtai Company Information
6.4.2 Bio Kangtai Description and Business Overview
6.4.3 Bio Kangtai Hepatitis B Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Bio Kangtai Hepatitis B Vaccines Product Portfolio
6.4.5 Bio Kangtai Recent Developments/Updates
6.5 Dynavax
6.5.1 Dynavax Company Information
6.5.2 Dynavax Description and Business Overview
6.5.3 Dynavax Hepatitis B Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Dynavax Hepatitis B Vaccines Product Portfolio
6.5.5 Dynavax Recent Developments/Updates
6.6 AIM Vaccine
6.6.1 AIM Vaccine Company Information
6.6.2 AIM Vaccine Description and Business Overview
6.6.3 AIM Vaccine Hepatitis B Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 AIM Vaccine Hepatitis B Vaccines Product Portfolio
6.6.5 AIM Vaccine Recent Developments/Updates
6.7 KM Biologics
6.7.1 KM Biologics Company Information
6.7.2 KM Biologics Description and Business Overview
6.7.3 KM Biologics Hepatitis B Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 KM Biologics Hepatitis B Vaccines Product Portfolio
6.7.5 KM Biologics Recent Developments/Updates
6.8 LG Life Sciences
6.8.1 LG Life Sciences Company Information
6.8.2 LG Life Sciences Description and Business Overview
6.8.3 LG Life Sciences Hepatitis B Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 LG Life Sciences Hepatitis B Vaccines Product Portfolio
6.8.5 LG Life Sciences Recent Developments/Updates
6.9 Serum Institute
6.9.1 Serum Institute Company Information
6.9.2 Serum Institute Description and Business Overview
6.9.3 Serum Institute Hepatitis B Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Serum Institute Hepatitis B Vaccines Product Portfolio
6.9.5 Serum Institute Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Hepatitis B Vaccines Industry Chain Analysis
7.2 Hepatitis B Vaccines Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Hepatitis B Vaccines Production Mode & Process Analysis
7.4 Hepatitis B Vaccines Sales and Marketing
7.4.1 Hepatitis B Vaccines Sales Channels
7.4.2 Hepatitis B Vaccines Distributors
7.5 Hepatitis B Vaccines Customer Analysis
8 Hepatitis B Vaccines Market Dynamics
8.1 Hepatitis B Vaccines Industry Trends
8.2 Hepatitis B Vaccines Market Drivers
8.3 Hepatitis B Vaccines Market Challenges
8.4 Hepatitis B Vaccines Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Hepatitis B Vaccines Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Hepatitis B Vaccines Market Value by Form Factor & Presentation (US$ Million), 2025 vs 2032
Table 3. Global Hepatitis B Vaccines Market Value by Adjuvant System (US$ Million), 2025 vs 2032
Table 4. Global Hepatitis B Vaccines Market Value by Application (US$ Million), 2025 vs 2032
Table 5. Global Hepatitis B Vaccines Market Competitive Situation by Manufacturers in 2025
Table 6. Global Hepatitis B Vaccines Sales (M Doses) of Key Manufacturers (2021–2026)
Table 7. Global Hepatitis B Vaccines Sales Market Share by Manufacturers (2021–2026)
Table 8. Global Hepatitis B Vaccines Revenue (US$ Million) by Manufacturers (2021–2026)
Table 9. Global Hepatitis B Vaccines Revenue Share by Manufacturers (2021–2026)
Table 10. Global Market Hepatitis B Vaccines Average Price (US$/Dose) of Key Manufacturers (2021–2026)
Table 11. Global Key Players of Hepatitis B Vaccines, Industry Ranking, 2023 vs 2024 vs 2025
Table 12. Global Key Manufacturers of Hepatitis B Vaccines, Manufacturing Sites and Headquarters
Table 13. Global Key Manufacturers of Hepatitis B Vaccines, Product Types and Applications
Table 14. Global Key Manufacturers of Hepatitis B Vaccines, Date of Entry into the Industry
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Hepatitis B Vaccines Companies by Tier (Tier 1, Tier 2, Tier 3), based on Hepatitis B Vaccines Revenue, 2025
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 18. Global Hepatitis B Vaccines Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 19. Global Hepatitis B Vaccines Sales by Region (M Doses), 2021–2026
Table 20. Global Hepatitis B Vaccines Sales Market Share by Region (2021–2026)
Table 21. Global Hepatitis B Vaccines Sales by Region (M Doses), 2027–2032
Table 22. Global Hepatitis B Vaccines Sales Market Share by Region (2027–2032)
Table 23. Global Hepatitis B Vaccines Revenue by Region (US$ Million), 2021–2026
Table 24. Global Hepatitis B Vaccines Revenue Market Share by Region (2021–2026)
Table 25. Global Hepatitis B Vaccines Revenue by Region (US$ Million), 2027–2032
Table 26. Global Hepatitis B Vaccines Revenue Market Share by Region (2027–2032)
Table 27. North America Hepatitis B Vaccines Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 28. North America Hepatitis B Vaccines Sales by Country (M Doses), 2021–2026
Table 29. North America Hepatitis B Vaccines Sales by Country (M Doses), 2027–2032
Table 30. North America Hepatitis B Vaccines Revenue by Country (US$ Million), 2021–2026
Table 31. North America Hepatitis B Vaccines Revenue by Country (US$ Million), 2027–2032
Table 32. Europe Hepatitis B Vaccines Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 33. Europe Hepatitis B Vaccines Sales by Country (M Doses), 2021–2026
Table 34. Europe Hepatitis B Vaccines Sales by Country (M Doses), 2027–2032
Table 35. Europe Hepatitis B Vaccines Revenue by Country (US$ Million), 2021–2026
Table 36. Europe Hepatitis B Vaccines Revenue by Country (US$ Million), 2027–2032
Table 37. Asia Pacific Hepatitis B Vaccines Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 38. Asia Pacific Hepatitis B Vaccines Sales by Region (M Doses), 2021–2026
Table 39. Asia Pacific Hepatitis B Vaccines Sales by Region (M Doses), 2027–2032
Table 40. Asia Pacific Hepatitis B Vaccines Revenue by Region (US$ Million), 2021–2026
Table 41. Asia Pacific Hepatitis B Vaccines Revenue by Region (US$ Million), 2027–2032
Table 42. Latin America Hepatitis B Vaccines Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 43. Latin America Hepatitis B Vaccines Sales by Country (M Doses), 2021–2026
Table 44. Latin America Hepatitis B Vaccines Sales by Country (M Doses), 2027–2032
Table 45. Latin America Hepatitis B Vaccines Revenue by Country (US$ Million), 2021–2026
Table 46. Latin America Hepatitis B Vaccines Revenue by Country (US$ Million), 2027–2032
Table 47. Middle East and Africa Hepatitis B Vaccines Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 48. Middle East and Africa Hepatitis B Vaccines Sales by Country (M Doses), 2021–2026
Table 49. Middle East and Africa Hepatitis B Vaccines Sales by Country (M Doses), 2027–2032
Table 50. Middle East and Africa Hepatitis B Vaccines Revenue by Country (US$ Million), 2021–2026
Table 51. Middle East and Africa Hepatitis B Vaccines Revenue by Country (US$ Million), 2027–2032
Table 52. Global Hepatitis B Vaccines Sales (M Doses) by Type (2021–2026)
Table 53. Global Hepatitis B Vaccines Sales (M Doses) by Type (2027–2032)
Table 54. Global Hepatitis B Vaccines Sales Market Share by Type (2021–2026)
Table 55. Global Hepatitis B Vaccines Sales Market Share by Type (2027–2032)
Table 56. Global Hepatitis B Vaccines Revenue (US$ Million) by Type (2021–2026)
Table 57. Global Hepatitis B Vaccines Revenue (US$ Million) by Type (2027–2032)
Table 58. Global Hepatitis B Vaccines Revenue Market Share by Type (2021–2026)
Table 59. Global Hepatitis B Vaccines Revenue Market Share by Type (2027–2032)
Table 60. Global Hepatitis B Vaccines Price (US$/Dose) by Type (2021–2026)
Table 61. Global Hepatitis B Vaccines Price (US$/Dose) by Type (2027–2032)
Table 62. Global Hepatitis B Vaccines Sales (M Doses) by Application (2021–2026)
Table 63. Global Hepatitis B Vaccines Sales (M Doses) by Application (2027–2032)
Table 64. Global Hepatitis B Vaccines Sales Market Share by Application (2021–2026)
Table 65. Global Hepatitis B Vaccines Sales Market Share by Application (2027–2032)
Table 66. Global Hepatitis B Vaccines Revenue (US$ Million) by Application (2021–2026)
Table 67. Global Hepatitis B Vaccines Revenue (US$ Million) by Application (2027–2032)
Table 68. Global Hepatitis B Vaccines Revenue Market Share by Application (2021–2026)
Table 69. Global Hepatitis B Vaccines Revenue Market Share by Application (2027–2032)
Table 70. Global Hepatitis B Vaccines Price (US$/Dose) by Application (2021–2026)
Table 71. Global Hepatitis B Vaccines Price (US$/Dose) by Application (2027–2032)
Table 72. GSK Company Information
Table 73. GSK Description and Business Overview
Table 74. GSK Hepatitis B Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 75. GSK Hepatitis B Vaccines Product
Table 76. GSK Recent Developments/Updates
Table 77. NCPC Company Information
Table 78. NCPC Description and Business Overview
Table 79. NCPC Hepatitis B Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 80. NCPC Hepatitis B Vaccines Product
Table 81. NCPC Recent Developments/Updates
Table 82. Merck Company Information
Table 83. Merck Description and Business Overview
Table 84. Merck Hepatitis B Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 85. Merck Hepatitis B Vaccines Product
Table 86. Merck Recent Developments/Updates
Table 87. Bio Kangtai Company Information
Table 88. Bio Kangtai Description and Business Overview
Table 89. Bio Kangtai Hepatitis B Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 90. Bio Kangtai Hepatitis B Vaccines Product
Table 91. Bio Kangtai Recent Developments/Updates
Table 92. Dynavax Company Information
Table 93. Dynavax Description and Business Overview
Table 94. Dynavax Hepatitis B Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 95. Dynavax Hepatitis B Vaccines Product
Table 96. Dynavax Recent Developments/Updates
Table 97. AIM Vaccine Company Information
Table 98. AIM Vaccine Description and Business Overview
Table 99. AIM Vaccine Hepatitis B Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 100. AIM Vaccine Hepatitis B Vaccines Product
Table 101. AIM Vaccine Recent Developments/Updates
Table 102. KM Biologics Company Information
Table 103. KM Biologics Description and Business Overview
Table 104. KM Biologics Hepatitis B Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 105. KM Biologics Hepatitis B Vaccines Product
Table 106. KM Biologics Recent Developments/Updates
Table 107. LG Life Sciences Company Information
Table 108. LG Life Sciences Description and Business Overview
Table 109. LG Life Sciences Hepatitis B Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 110. LG Life Sciences Hepatitis B Vaccines Product
Table 111. LG Life Sciences Recent Developments/Updates
Table 112. Serum Institute Company Information
Table 113. Serum Institute Description and Business Overview
Table 114. Serum Institute Hepatitis B Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 115. Serum Institute Hepatitis B Vaccines Product
Table 116. Serum Institute Recent Developments/Updates
Table 117. Key Raw Materials Lists
Table 118. Raw Materials Key Suppliers Lists
Table 119. Hepatitis B Vaccines Distributors List
Table 120. Hepatitis B Vaccines Customers List
Table 121. Hepatitis B Vaccines Market Trends
Table 122. Hepatitis B Vaccines Market Drivers
Table 123. Hepatitis B Vaccines Market Challenges
Table 124. Hepatitis B Vaccines Market Restraints
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
Table 128. Authors List of This Report
List of Figures
Figure 1. Product Picture of Hepatitis B Vaccines
Figure 2. Global Hepatitis B Vaccines Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Hepatitis B Vaccines Market Share by Type: 2025 & 2032
Figure 4. Yeast Derived Product Picture
Figure 5. CHO Derived Product Picture
Figure 6. Global Hepatitis B Vaccines Market Value by Form Factor & Presentation (US$ Million), 2021–2032
Figure 7. Global Hepatitis B Vaccines Market Share by Form Factor & Presentation: 2025 vs 2032
Figure 8. Vial Presentation Product Picture
Figure 9. Prefilled Syringe Product Picture
Figure 10. Global Hepatitis B Vaccines Market Value by Adjuvant System (US$ Million), 2021–2032
Figure 11. Global Hepatitis B Vaccines Market Share by Adjuvant System: 2025 vs 2032
Figure 12. Aluminum Salt Adjuvant Product Picture
Figure 13. No Adjuvant Product Picture
Figure 14. Other Product Picture
Figure 15. Global Hepatitis B Vaccines Market Value by Application (US$ Million), 2021–2032
Figure 16. Global Hepatitis B Vaccines Market Share by Application: 2025 & 2032
Figure 17. Children
Figure 18. Adult
Figure 19. Global Hepatitis B Vaccines Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 20. Global Hepatitis B Vaccines Market Size (US$ Million), 2021–2032
Figure 21. Global Hepatitis B Vaccines Sales (M Doses), 2021–2032
Figure 22. Global Hepatitis B Vaccines Average Price (US$/Dose), 2021–2032
Figure 23. Hepatitis B Vaccines Report Years Considered
Figure 24. Hepatitis B Vaccines Sales Share by Manufacturers in 2025
Figure 25. Global Hepatitis B Vaccines Revenue Share by Manufacturers in 2025
Figure 26. Top 5 and Top 10 Global Hepatitis B Vaccines Players: Market Share by Revenue in Hepatitis B Vaccines in 2025
Figure 27. Hepatitis B Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 28. Global Hepatitis B Vaccines Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 29. North America Hepatitis B Vaccines Sales Market Share by Country (2021–2032)
Figure 30. North America Hepatitis B Vaccines Revenue Market Share by Country (2021–2032)
Figure 31. U.S. Hepatitis B Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Canada Hepatitis B Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Europe Hepatitis B Vaccines Sales Market Share by Country (2021–2032)
Figure 34. Europe Hepatitis B Vaccines Revenue Market Share by Country (2021–2032)
Figure 35. Germany Hepatitis B Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. France Hepatitis B Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. U.K. Hepatitis B Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Italy Hepatitis B Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Russia Hepatitis B Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Asia Pacific Hepatitis B Vaccines Sales Market Share by Region (2021–2032)
Figure 41. Asia Pacific Hepatitis B Vaccines Revenue Market Share by Region (2021–2032)
Figure 42. China Hepatitis B Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Japan Hepatitis B Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. South Korea Hepatitis B Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. India Hepatitis B Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Australia Hepatitis B Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. China Taiwan Hepatitis B Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Indonesia Hepatitis B Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Thailand Hepatitis B Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Malaysia Hepatitis B Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Philippines Hepatitis B Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Latin America Hepatitis B Vaccines Sales Market Share by Country (2021–2032)
Figure 53. Latin America Hepatitis B Vaccines Revenue Market Share by Country (2021–2032)
Figure 54. Mexico Hepatitis B Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Brazil Hepatitis B Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Argentina Hepatitis B Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 57. Middle East and Africa Hepatitis B Vaccines Sales Market Share by Country (2021–2032)
Figure 58. Middle East and Africa Hepatitis B Vaccines Revenue Market Share by Country (2021–2032)
Figure 59. Turkey Hepatitis B Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 60. Saudi Arabia Hepatitis B Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 61. UAE Hepatitis B Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 62. Global Sales Market Share of Hepatitis B Vaccines by Type (2021–2032)
Figure 63. Global Revenue Market Share of Hepatitis B Vaccines by Type (2021–2032)
Figure 64. Global Hepatitis B Vaccines Price (US$/Dose) by Type (2021–2032)
Figure 65. Global Sales Market Share of Hepatitis B Vaccines by Application (2021–2032)
Figure 66. Global Revenue Market Share of Hepatitis B Vaccines by Application (2021–2032)
Figure 67. Global Hepatitis B Vaccines Price (US$/Dose) by Application (2021–2032)
Figure 68. Hepatitis B Vaccines Value Chain
Figure 69. Channels of Distribution (Direct Vs Distribution)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
